Immunologic Response to Secukinumab in Plaque Psoriasis
Status:
Completed
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label study, which will examine the effect of secukinumab on the
immunologic and genetic environment within psoriatic lesions.